Hahka-Kemppinen M, Muhonen T, Kangas L, Pyrhönen S
Department of Oncology, Helsinki University Central Hospital, Finland.
Melanoma Res. 1996 Jun;6(3):215-21. doi: 10.1097/00008390-199606000-00004.
We have analysed the chemosensitivity of 121 human melanoma metastases in the 6-day mouse subrenal capsule assay (SRCA). A total of 13 different chemotherapy regimens were analysed in four successive series. By the original criteria of the assay, 75% of tumours were sensitive to at least one regimen. The most effective combinations, giving sensitivity rates > 40%, were of dacarbazine, vincristine, and BCNU (DOB) with or without metronidazole, followed by cisplatin plus etoposide (Plat-VP16) combined with interferon. On the basis of the SRCA screening we developed a four-drug chemotherapy regimen combined with interferon for metastatic melanoma. Retrospectively analysed the assay correctly identified 77% of clinical responders and 54% of clinical non-responders. The overall predictive accuracy was 65%. Despite the limitations of the assay, it can be used for screening new drugs or combinations.
我们在为期6天的小鼠肾包膜下试验（SRCA）中分析了121例人类黑色素瘤转移灶的化学敏感性。在连续四个系列中分析了总共13种不同的化疗方案。根据该试验的原始标准，75%的肿瘤对至少一种方案敏感。最有效的组合，即敏感率>40%的组合，是达卡巴嗪、长春新碱和卡莫司汀（DOB）加或不加甲硝唑，其次是顺铂加依托泊苷（Plat-VP16）联合干扰素。基于SRCA筛选，我们为转移性黑色素瘤制定了一种联合干扰素的四联化疗方案。回顾性分析显示，该试验正确识别了77%的临床反应者和54%的临床无反应者。总体预测准确率为65%。尽管该试验存在局限性，但它可用于筛选新药或联合用药。
